Imago

About the offering

Why Imago Rehab? Imago Rehab is transforming recovery for the 100M+ Americans living with neurological and cardiovascular conditions. Leveraging AI and wearable robotics, Imago Rehab’s clinician-led telerehab platform provides patients with comprehensive in-home therapy, for the first time ever. Led by entrepreneurs, clinicians, and engineers from Harvard University, MIT, Humana, CVS/Aetna, Anthem, and Intel, and backed by investors AARP, Safar Partners, and Cybernetix, Imago Rehab is revolutionizing the $210B neurological and cardiovascular rehab market. With outcomes 5X better than in-clinic therapy, Imago Rehab is delivering the unprecedented recovery results that patients deserve. We're achieving unprecedented outcomes In just two years, Imago Rehab has hit three critical milestones: superior clinical outcomes, broad insurance coverage, and exceptional cost efficiency. 5x BETTER RECOVERY OUTCOMES - Patients achieve five times better recovery outcomes than traditional, in-clinic rehab 23 INSURER PARTNERSHIPS - Covered across 8 states, including Medicare, United Healthcare, Humana, Anthem and various BlueCross BlueShield plans 40x $10,000 LTV : $250 CAC - Efficient and scalable business model Rehabilitation for neurologic and cardiovascular disease is frozen in the past For those who survive cardiovascular and neurologic events, such as peripheral artery disease, heart failure, and stroke, life often changes instantly. Once simple tasks like getting dressed, cooking a meal, or walking down the sidewalk with a loved one can become near impossible. Every 40 seconds someone in the U.S. has a stroke. 100 million Americans suffer from cardiovascular and neurological injuries annually. Patients who are recovering from these events are prescribed various forms of rehabilitation therapy, but access is complex. With only a few high-quality rehabilitation centers available, patients nationwide struggle to access care. Even when accessing care isn’t an issue, in-clinic therapy programs fall short. The logistical barriers, lack of continuity between clinic and day-to-day activities, and limited service availability leads to high attrition rates of over 30%, poor outcomes, and, in many cases, permanent disability. These challenges place a significant emotional and financial toll on survivors and their families, adding to a cycle of hopelessness. There is a critical need for a therapy solution that works. Imago's clinician-led, Al-powered platform delivers personalized rehab with robotic wearables Imago Rehab makes rehab convenient and effective. The Imago Platform integrates a telerehab clinic, wearable robotic devices, and advanced AI analysis to deliver highly personalized rehabilitation programs that work. Imago Rehab uses AI to make real-time adjustments to therapy programs, provides asynchronous education to sustain progress between visits, and securely reports patient progress through Electronic Health Records (EHR) to coordinate care across clinicians and ensure a holistic approach to each patient’s recovery. At the heart of our platform is our patent-protected Imago Glove. This innovative device is currently used to accelerate stroke recovery through personalized and gamified therapy programs and exercises. This system delivers high-repetition, high-intensity exercises, which can be completed from the comfort of home. These exercises are essential for neuroplasticity and recovery and lead to superior recovery outcomes. -2 Patents granted -10X More repetitions than traditional rehab -These patents are under Harvard University's name and are exclusively licensed to Imago. Our unique integration of wearable, robotic technology and customized rehab programs ensures that effective therapy extends into the home environment, bridging the critical gap left by traditional therapy solutions. The Imago platform enables in-home stroke & cardiovascular therapy for the first time ever We make home recovery possible by seamlessly integrating rehabilitation into daily activities from the comfort of home. By eradicating the need for in-person rehab visits, the path to recovery is convenient, accessible, and personalized to each patient’s needs. "As a neurologist, I'm excited to be working with the Imago Rehab team. Patients with stroke have difficulty accessing high quality rehabilitation care. Imago Rehab has solved this challenge with an evidence-based, high dose, high intensity, and comprehensive virtual program. The care delivery model and outcomes achieved through this program for my patients have been terrific!" - DR. DAVID LIN, DIRECTOR NEURORECOVERY CLINIC MASSACHUSETTS GENERAL HOSPITAL, ASSISTANT PROFESSOR NEUROLOGY HARVARD MEDICAL SCHOOL Our patients rave about their recovery transformations Imago users report substantial improvements in physical function and independence, delivering outcomes that are 5x better than traditional therapies, impressing patients and clinicians. Our breakthrough solutions are transforming lives, with patients and clinicians recognizing the exceptional, unprecedented results. Our team has scaled a company to IPO and is led by executives from Harvard, MIT, Humana, CVS/Aetna, Elevance Health, and Intel Imago Rehab’s team is a dynamic powerhouse of experts from Harvard, MIT, Humana, CVS/Aetna, Anthem, Intel, and leading innovators in healthcare and engineering. With 10 decades of combined experience, including working for insurers impacting 42M healthcare subscribers, managing a $7B+ clinical spend portfolio, and bringing a company to IPO, our team excels at bridging the gap between cutting-edge technology and patient-centered healthcare solutions. "An investment in Imago Rehab is an exciting and unique opportunity for the public to directly invest in a digital health platform that has already shown significant improvement in the care and outcomes of stroke survivors. This investment is an opportunity to drastically improve the lives of over 5 million stroke survivors with lasting motor impairment and revolutionize the $38 billion stroke rehabilitation market through Imago's superior telehealth virtual clinic therapies and devices." - ARUNAS CHESONIS, MANAGING PARTER, SAFAR PARTNERS We're leading the charge in the $210B rehab market The need for effective and accessible solutions has never been greater and Imago Rehab is at the forefront of innovation for neurological and cardiovascular recovery - a $210B market. Imago is set to revolutionize the market by integrating robotic technology with clinician-led care. Our telerehab platform addresses immediate rehabilitation needs and opens doors to orthopedic, pulmonary, and geriatric rehab care. We envision a future where all rehabilitation needs are met effortlessly in a market owned by Imago Rehab. Rapid commercialization via existing claim codes & an impressive LTV:CAC ratio Our business model seamlessly integrates advanced technology with personalized, clinician-led care, ensuring high profitability and significant growth opportunities. By leveraging existing claims codes with our insurer partnerships, we accelerate our market entry and reduce approval risk, paving the way for rapid commercialization. This is backed by an impressive Lifetime Value (LTV) to Customer Acquisition Cost (CAC) ratio of 40X. Our revenue is generated from two primary sources: 1) insurance-covered therapy services 2) wearable devices, including the Imago Glove Our robust partnerships with 23 insurers, including Medicare, Harvard Pilgrim HealthCare, United Healthcare, Humana, Anthem and other BlueCross BlueShield plans, guarantee broad access and affordability, with the potential to reach 311M patients. On average, each patient is granted 50 visits per year with over $5K in reimbursements. We're on track to exceed $56.5M in therapy and device sales by 2028 *Projections not guaranteed Imago Rehab is strategically positioned to exceed $56.5M in therapy and device sales by 2028. For these projections, we assume the patient referral partnership we have secured will generate a minimum of 100 new patient referrals each month in 2025. We expect to need $4.5M to reach profitability. We’re currently raising $2.5M this round. We’ll raise $2M in a future round to reach profitability ahead of a Series A in the $7-9M range. We believe this will allow faster growth, greater revenue opportunities, and position us well for these projections. Our vision is to bring neurological and cardiovascular rehab into the Al and robotics future By developing additional robotic wearables with the Harvard Lab, forming more insurer partnerships, and extending our services to adapt to market needs across the United States, we’re set for rapid expansion and mainstream adoption. We’re focused on achieving these 4 key strategic milestones: 1) Expand Service Across 50 States: Increase our service reach across the U.S. by the end of 2027. 2) Grow Patient Numbers and ARR: Boost our Patient Base and Annual Recurring Revenue by 394% within the next year. 3) Advance Tech Platform & Release a Patient App: Enhance our technology platform and launch a dedicated patient app by the end of 2024. 4) Develop Version 2.0 of the Imago Glove: Create the next generation of our wearable technology, scheduled for release in early 2027. Following the footsteps of digital health giants Digital health companies have been on a tear as more demonstrate the business case and profitability of their models. This successful approach has never been applied to cardiovascular and neurological rehabilitation—until now. Imago Rehab’s integration of advanced robotics and AI with deep clinical expertise positions us to achieve incredible business outcomes for our investors. Invest in the Future of Rehabilitation The demand for advanced rehabilitation solutions has never been higher. Investing in Imago Rehab means more than supporting groundbreaking AI and robotic technology, it means investing in a future where millions can regain their independence and quality of life. Our community round democratizes healthcare innovation, allowing you to invest on the same terms as top investors like AARP, Safar Partners, and Cybernetix. Together we can transform rehabilitation as we know it, ensuring better outcomes for millions of patients.

FAQ